-

Insulet to Present at Upcoming Investor Conferences

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at two upcoming investor conferences:

  • The Raymond James & Associates 44th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 7, 2023 at 9:15 a.m. (Eastern Time)
  • The Cowen 43rd Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2023 at 10:30 a.m. (Eastern Time).

To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will also be available following the events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

©2023 Insulet Corporation. Omnipod and Omnipod 5 are registered trademarks of Insulet Corporation.

Contacts

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

Insulet Corporation

NASDAQ:PODD

Release Versions

Contacts

Investor Relations:

Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Media:

Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

More News From Insulet Corporation

Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the publication of its 2025 Sustainability Report, showcasing progress across its operations, products, people, and community. The report underscores how Insulet’s sustainability strategy continues to strengthen its mission of transforming life for people with diabetes while preserving the health of...

Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes...

Insulet to Participate in BofA Securities 2026 Health Care Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Wednesday, May 13, 2026 at 9:20 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet C...
Back to Newsroom